183 related articles for article (PubMed ID: 32793906)
21. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
[TBL] [Abstract][Full Text] [Related]
22. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
Bertoglio F; Fühner V; Ruschig M; Heine PA; Abassi L; Klünemann T; Rand U; Meier D; Langreder N; Steinke S; Ballmann R; Schneider KT; Roth KDR; Kuhn P; Riese P; Schäckermann D; Korn J; Koch A; Chaudhry MZ; Eschke K; Kim Y; Zock-Emmenthal S; Becker M; Scholz M; Moreira GMSG; Wenzel EV; Russo G; Garritsen HSP; Casu S; Gerstner A; Roth G; Adler J; Trimpert J; Hermann A; Schirrmann T; Dübel S; Frenzel A; Van den Heuvel J; Čičin-Šain L; Schubert M; Hust M
Cell Rep; 2021 Jul; 36(4):109433. PubMed ID: 34273271
[TBL] [Abstract][Full Text] [Related]
23. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
24. The structure of the RBD-E77 Fab complex reveals neutralization and immune escape of SARS-CoV-2.
Zhang Z; Li X; Xue Y; Yang B; Jia Y; Liu S; Lu D
Acta Crystallogr D Struct Biol; 2023 Aug; 79(Pt 8):746-757. PubMed ID: 37428848
[TBL] [Abstract][Full Text] [Related]
25. Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants.
Li T; Zhou B; Luo Z; Lai Y; Huang S; Zhou Y; Li Y; Gautam A; Bourgeau S; Wang S; Bao J; Tan J; Lavillette D; Li D
Front Microbiol; 2022; 13():875840. PubMed ID: 35722331
[TBL] [Abstract][Full Text] [Related]
26. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies.
Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Cetrulo Lorenzi JC; Finkin S; Hagglof T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
bioRxiv; 2020 May; ():. PubMed ID: 32577645
[TBL] [Abstract][Full Text] [Related]
27. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
28. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.
Wu NC; Yuan M; Bangaru S; Huang D; Zhu X; Lee CD; Turner HL; Peng L; Yang L; Nemazee D; Ward AB; Wilson IA
bioRxiv; 2020 Sep; ():. PubMed ID: 32995788
[TBL] [Abstract][Full Text] [Related]
29. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain.
Wu NC; Yuan M; Liu H; Lee CD; Zhu X; Bangaru S; Torres JL; Caniels TG; Brouwer PJM; van Gils MJ; Sanders RW; Ward AB; Wilson IA
Cell Rep; 2020 Oct; 33(3):108274. PubMed ID: 33027617
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.
Yu W; Wu X; Ren J; Zhang X; Wang Y; Li C; Xu W; Li J; Li G; Zheng W; Liao H; Yuan X
Comb Chem High Throughput Screen; 2021; 24(7):1069-1082. PubMed ID: 33106140
[TBL] [Abstract][Full Text] [Related]
31. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
[TBL] [Abstract][Full Text] [Related]
32. A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
Hua RH; Zhang SJ; Niu B; Ge JY; Lan T; Bu ZG
Microbiol Spectr; 2023 Aug; 11(4):e0119023. PubMed ID: 37306579
[TBL] [Abstract][Full Text] [Related]
33. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability.
Burnett DL; Jackson KJL; Langley DB; Aggrawal A; Stella AO; Johansen MD; Balachandran H; Lenthall H; Rouet R; Walker G; Saunders BM; Singh M; Li H; Henry JY; Jackson J; Stewart AG; Witthauer F; Spence MA; Hansbro NG; Jackson C; Schofield P; Milthorpe C; Martinello M; Schulz SR; Roth E; Kelleher A; Emery S; Britton WJ; Rawlinson WD; Karl R; Schäfer S; Winkler TH; Brink R; Bull RA; Hansbro PM; Jäck HM; Turville S; Christ D; Goodnow CC
Immunity; 2021 Dec; 54(12):2908-2921.e6. PubMed ID: 34788600
[TBL] [Abstract][Full Text] [Related]
34. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients.
Luo YR; Yun C; Chakraborty I; Wu AHB; Lynch KL
J Clin Microbiol; 2021 Jun; 59(7):e0019321. PubMed ID: 33827900
[TBL] [Abstract][Full Text] [Related]
35. Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization.
Byazrova M; Gattinger P; Astakhova E; Hofer G; Khaitov M; Filatov A; Valenta R
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982183
[TBL] [Abstract][Full Text] [Related]
36. Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins.
Shi Y; Shi J; Sun L; Tan Y; Wang G; Guo F; Hu G; Fu Y; Fu ZF; Xiao S; Peng G
J Virol; 2021 Mar; 95(7):. PubMed ID: 33414160
[TBL] [Abstract][Full Text] [Related]
37. A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD.
Wang X; Hu A; Chen X; Zhang Y; Yu F; Yue S; Li A; Zhang J; Pan Z; Yang Y; Lin Y; Gao L; Zhou J; Zhao J; Li F; Shi Y; Huang F; Yang X; Peng Y; Tu L; Zhang H; Zheng H; He J; Zhang H; Xu L; Huang Q; Zhu Y; Deng K; Ye L
Signal Transduct Target Ther; 2022 Apr; 7(1):114. PubMed ID: 35383141
[TBL] [Abstract][Full Text] [Related]
38. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
39. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
[TBL] [Abstract][Full Text] [Related]
40. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design.
Scheiblauer H; Nübling CM; Wolf T; Khodamoradi Y; Bellinghausen C; Sonntagbauer M; Esser-Nobis K; Filomena A; Mahler V; Maier TJ; Stephan C
J Clin Virol; 2022 Jan; 146():105052. PubMed ID: 34920374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
